ATLANTA, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Femasys Inc., (Nasdaq: FEMY), a leading biomedical innovator addressing significant unmet needs in women's health worldwide, with a broad portfolio of ...

With fertility rates at historic lows, Femasys advances access to early infertility care through FemaSeed® Complete, enabling ...

Publication of positive data in a leading peer-reviewed journal enhances credibility and visibility for FemBloc, attracting interest from the medical community. The reported pregnancy rate of 0% among ...

--Initiation of access to FemBloc, a revolutionary non-surgical permanent contraceptive, as global availability accelerates-- ATLANTA, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a ...

-- FemBloc becomes the latest Femasys product to achieve MDSAP certification, building on a proven track record of compliance -- ATLANTA, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), ...

Femasys Inc. announced the achievement of CE mark certification for the FemBloc delivery system, marking it as the first regulatory approval in the world for a non-surgical permanent birth control ...

ATLANTA, March 13, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (FEMY),, a leading biomedical innovator addressing significant unmet needs in women's health worldwide, with a broad portfolio of disruptive, ...

-- Enrollment begins in the FDA-authorized FINALE pivotal trial evaluating FemBloc, a first-of-its-kind non-surgical permanent birth control, following positive clinical data -- ATLANTA, March 10, ...

ATLANTA, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective to ...

ATLANTA, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective to ...